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ABSTRACT
Long-term treatment with glucocorticoids (GCs) leads to a rapid bone loss and to a greater risk of fractures.
To evaluate the specific effects of this treatment on cancellous bone remodeling, structure, and microarchi-
tecture, we compared 22 transiliac biopsy specimens taken in postmenopausal women (65 6 6 years) receiving
GCs (>7.5 mg/day, for at least 6 months) and 22 biopsy specimens taken in age-matched women with
postmenopausal osteoporosis (PMOP), all untreated and having either at least one vertebral fracture or a T
score < 22.5 SD. On these biopsy specimens, we measured static and dynamic parameters reflecting
trabecular bone formation and resorption. Also, we performed the strut analysis and evaluated the trabecular
bone pattern factor (TBPf), Euler number/tissue volume (E/TV), interconnectivity index (ICI), and marrow
star volume (MaSV). Glucocorticoid-induced osteoporosis (GIOP), when compared with PMOP, was char-
acterized by lower bone volume (BV/TV), trabecular thickness (Tb.Th), wall thickness (W.Th), osteoid
thickness (O.Th), bone formation rate/bone surface (BFR/BS), adjusted mineral apposition rate/bone surface
(Aj.AR/BS), and higher ICI and resorption parameters. After adjustment for BV/TV, the W.Th remained
significantly lower in GIOP (p < 0.0001). The active formation period [FP(a1)] was not different. Patients
with GIOP were divided into two groups: high cumulative dose GCs (HGCs; 23.7 6 9.7 g) and low cumulative
dose GCs (LGCs; 2.7 6 1.2 g). HGC when compared with LGC was characterized by lower W.Th (p < 0.05),
BV/TV (p < 0.001), Tb.Th (p < 0.05), trabecular number (Tb.N; p < 0.05), FP(a1) (p < 0.05), and nodes (p <
0.05), and higher E/TV (p < 0.05), ICI (p < 0.005), and TBPf (p < 0.05). When HGC was compared with
PMOP, the results were similar except for the MaSV, which was significantly higher (p < 0.005). In summary,
GIOP was characterized by lower formation and higher resorption than in PMOP, already present after LGC.
With HGCs, these changes were associated with a more dramatic bone loss caused by a major loss of
trabecular connectivity. (J Bone Miner Res 2001;16:97–103)
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INTRODUCTION
PROLONGED glucocorticoid (GC) therapy is well recog-nized as an independent risk factor of osteoporosis and
fractures.(1–3) The overall incidence of osteoporosis in pa-
tients taking GCs for over 6 months is approximately
50%(4,5) and the incidence of fractures is about 30% after 5
years of treatment.(6) Nevertheless, this treatment represents
one of the most important approaches in several chronic
diseases such as rheumatoid arthritis or asthma and after
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organ transplantation. In these conditions, GC-induced os-
teoporosis (GIOP) represents a major problem.(7,8) Previous
studies have indicated that bone mineral density (BMD) was
decreased at different sites(9,10) and that the risk of fracture
was high after GC treatment,(3,6,11) as a result of marked
inhibition of osteoblastic activity, confirmed in animal stud-
ies.(12) This osteoblastic dysfunction has been associated
with an increased osteoclastic bone resorption,(13) second-
ary to a decreased calcium absorption inducing a secondary
hyperparathyroidism.(14–16) More recently, it also has been
suggested that the osteoblastic dysfunction could be caused
by the GC-mediated inhibition of osteoblastogenesis and
promotion of apoptosis of osteoblastic cells.(17)
At the histological level, the histomorphometric analysis
of iliac crest biopsy specimens taken from GC-treated pa-
tients has shown a decrease in the wall thickness (W.Th) of
trabecular packets and as a consequence in the trabecular
thickness (Tb.Th) and trabecular bone volume.(18–20) How-
ever, there are few published data about the trabecular
microarchitecture in GIOP. In GC-treated men compared
with age-matched controls, exponential relationships have
been found between the bone volume and various connec-
tivity parameters.(20) Furthermore, in women with post-
menopausal osteoporosis (PMOP) compared with controls,
histomorphometric studies(21) have shown a significant de-
crease of 40% in the bone volume, Tb.Th and trabecular
number (Tb.N), W.Th, and active formation period
[FP(a1)], but without any significant difference in bone
formation at the tissue and bone mineral unit (BMU) levels.
Only Aaron et al. have compared GIOP with primary os-
teoporosis in a group of men and women and observed in
the primary osteoporosis group a decline in the Tb.N, as-
sociated with increased resorption, leading to plate perfora-
tions and to disruption of the three-dimensional (3D) tra-
becular architecture.(22)
Substantial advances have been accomplished in the
methods now available for the analysis of cancellous bone
structure on histological sections. These new evaluations
provide precise information concerning connectivity of the
trabecular network. Connectivity is a specific feature, which
describes different types of connection between nodes
(points at which three or more trabeculae joined), connec-
tion branches (struts), and terminal or free-end branches
(termini).(23) In addition, other parameters have been vali-
dated to assess indirectly bone microarchitecture through
the measurement of the marrow star volume (MaSV),(24)
Euler number,(25) trabecular bone pattern factor (TBPf),(26)
and interconnectivity index (ICI).(27) All these parameters
represent a more precise and interesting approach to bone
microarchitecture evaluation in 2D sections. In fact, high
values of these parameters (or less negative in the case of
Euler number) contribute to define a low degree of organi-
zation of trabecular network, showing a low connectivity
between the trabeculae.
The aim of this study was: (1) to assess GC effects on
microarchitecture and remodeling of cancellous iliac bone
in women by using the most recent 2D histomorphometric
approach; (2) to compare the microarchitectural character-
istics in two types of osteoporosis, GIOP and PMOP, in
untreated postmenopausal women; and (3) in GIOP, to
evaluate the influence of the cumulative dose of GC on the
histomorphometric parameters.
MATERIALS AND METHODS
Patients
Twenty-two transiliac biopsy specimens taken in un-
treated postmenopausal women aged 65 6 6 years who
received GC therapy (at least 7.5 mg/day of prednisone for
at least 6 months) were compared with 22 biopsy specimens
taken in women aged 66 6 11 years with PMOP. In both
groups osteoporosis was confirmed by the presence of at
least one vertebral fracture or by a T score , 22.5 after
dual-energy X-ray absorptiometry (DXA) evaluation at the
proximal femur. Ten patients in each group had one or more
vertebral fractures. None of the patients had ever been
treated for their bone condition and none presented with any
other disorders that could have affected bone metabolism.
Forty-two of the 44 patients were doubly labeled with
tetracycline (Lederle´, Oullins, France) before biopsy (de-
methylchlortetracycline, 600 mg per day, 2 days on, 12 days
off, and 2 days on). The patients who received GC therapy
were treated for rheumatic diseases, asthma, dermatologic
diseases, or intestinal diseases.
Histomorphometric analysis
In these undecalcified bone biopsy specimens taken with
a 7.5-mm inner-diameter Bordier-Meunier trephine (Lepine,
Lyon, France), we evaluated the histomorphometric param-
eters with either a semiautomatic (Ibas 1; Leica, Wetzlar,
Germany) or an automatic (Visiolab 1000; Biocom, Paris,
France) analyzer. The measurements of indirect parameters
of microarchitecture were carried out with modules devel-
oped at our institution. All parameters were expressed ac-
cording to the recommended American Society for Bone
and Mineral Research (ASBMR) nomenclature.(28) All mea-
surements of thickness were adjusted for obliquity of sec-
tions, by multiplying by p/4.(28)
Bone structure: We evaluated the W.Th (mm) of cancel-
lous packets, which represents the end product of the os-
teoblastic activity exerted in a remodeling site, under polar-
ized light on Solochrome cyanin–stained sections. We also
measured the cancellous bone volume/tissue volume (BV/
TV; %) on Goldner-stained sections.
Assessment of bone remodeling: To evaluate the remod-
eling, we measured the following parameters in cancellous
bone on Goldner-stained sections: osteoid surface/bone sur-
face (OS/BS; %), osteoid thickness (O.Th; mm), eroded
surface/bone surface (ES/BS; %), and osteoclast number/
bone surface (N.Oc/BS; /mm). Dynamic parameters also
were evaluated on unstained sections measured under UV
light: mineral apposition rate (MAR; mm/day) and miner-
alizing surface/bone surface (MS/BS; %). Bone formation
rate/bone surface (BFR/BS) was calculated as (MS/BS) 3
MAR (mm3/mm2 day), and adjusted apposition rate/bone
surface (Aj.AR/BS), that is, the BFR adjusted for osteoid,
was expressed as micrometers per day. FP(a1) was calcu-
lated as W.Th/MAR and expressed in days.
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Assessment of trabecular microarchitecture: Trabecular
number (Tb.N; mm), trabecular separation (Tb.Sp; mm),
and Tb.Th (mm) were calculated according to Parfitt form-
ula.(29) In addition, Tb.Th was evaluated by direct measure-
ment using a grid, as orthogonal intercepts from intersec-
tions of the grid lines with trabecular boundaries.(30)
After skeletonization, we evaluated trabecular network in
terms of number of nodes (N.Nd/TV) and number of node-
to-node branches (N.Nd-Nd/TV), expressed as percent of
tissue volume, node-to-node length (L.Nd-Nd/TSL), ex-
pressed as percent of total skeletonized structure length),
and nodes/termini ratio (Nd/Tm).
The following indirect parameters reflect the microarchi-
tecture that also were assessed: (1) The MaSV, that is, the
mean volume of all the parts of an object that can be
unobscured in all the directions from a point inside the
object. This parameter, by the analysis of marrow space
distribution, gives an indirect evaluation of the trabecular
network organization(24); for its automatic measure, the
method developed by Levitz was used.(31) (2) The Euler
number, expressed per tissue volume (E/TV), that is, the
number of holes minus the number of connected compo-
nents, which can be interpreted as the maximum number of
branches that could be removed without breaking the net-
work into different parts.(25) (3) The TBPf, that is, the
relation between convex and concave elements, considering
a concave element as expression of a well-connected struc-
ture.(26) (4) The ICI, after skeletonization of the bone mar-
row, defined as (N 3 NN)/[T 3 (NF 1 1)], where N is the
number of nodes, NN is the number of node-to-node
branches, NF is the number of node-to-terminus branches,
and T is the number of “trees,” a tree being an independent
portion of the medullary space totally enclosed by a trabec-
ular structure.(27) All these parameters, as well as the strut
analysis, contribute to describe the connectivity of the tra-
becular network.
Statistical analysis
All the results were expressed as mean 6 SD. For all the
variables having a Gaussian distribution, multiple group
comparisons were made by analysis of variance (ANOVA).
The Newman–Keuls test was performed as a post hoc test
for the difference between two groups. Simple regression
analysis was performed to evaluate the relationship between
two variables. All statistical analyses were performed with
Statistica software (Statsoft, Tulsa, OK, USA).
RESULTS
Bone remodeling
The values of remodeling parameters of the two groups
are shown in Table 1. When compared with PMOP, GIOP
showed a significantly lower bone formation because the
parameters reflecting bone formation at the tissue (BFR/BS)
and at the BMU levels (Aj.AR/BS) were decreased in
GIOP. FP(a1) was similar in the two groups. In contrast,
the GIOP group was characterized by a significant increase
in resorption parameters, with higher eroded surface and
osteoclast number.
Bone structure and microarchitecture
The calculated versus the direct measurement of Tb.Th
showed a high significant correlation (r 5 0.95; p ,
0.0001). For this study, the calculated one was used.
Table 2 shows the values of main structural and micro-
architectural parameters of the two groups. GIOP, when
compared with PMOP, was characterized by lower wall and
Tb.Th, and as a consequence, lower BV/TV. In addition, the
ICI was also higher in GIOP with higher Tb.Sp. After
adjustment for BV/TV, only the W.Th was still lower in
GIOP with respect to PMOP (29.8 6 2.5 mm vs. 23.3 6 3.1
mm; p , 0.0001).
Biopsy specimens from patients with GIOP were di-
vided into two groups with respect to the cumulative dose
of GCs: high cumulative dose glucocorticoid (HGC;
higher than 10 g of prednisone; mean, 23.7 6 9.7 g) and
low cumulative dose glucocorticoid (LGC; lower than
10 g of prednisone; mean, 2.7 6 1.2 g). The same number
of subjects composed each group. HGC when compared
with LGC showed significant lower W.Th, BV/TV,
Tb.Th, Tb.N, N.Nd/TV, N. Nd-Nd/TV, L.Nd-Nd/TSL,
TABLE 1. REMODELING PARAMETERS OF ILIAC TRABECULAR BONE FROM 22 WOMEN WITH PMOP AND
22 WOMEN WITH GIOP
Parameters PMOP GIOP p
Mean age (years) 66 6 11 65 6 6 NS
OS/BS (%) 5.77 6 3.36 8.34 6 9.55 NS
O.Th (mm)a 8.88 6 1.84 7.28 6 1.46 ,0.003
MAR (mm/day) 0.59 6 0.13 0.53 6 0.13 NS
MS/BS (%) 6.2 6 2.3 2.2 6 2.6 ,0.0001
BFR/BS (mm3/mm2 per day) 0.037 6 0.016 0.013 6 0.016 ,0.0005
Aj.AR/BS (mm/day) 0.83 6 0.73 0.22 6 0.16 ,0.005
FP(a1) (days) 53 6 11 47 6 13 NS
ES/BS (%) 2.18 6 1.24 4.06 6 2.45 ,0.005
N.Oc/BS (/mm) 0.06 6 0.10 0.12 6 0.04 ,0.05
a Adjusted for obliquity.
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and Nd/Tm and higher TBPf, E/TV, ICI, and MaSV
(Figs. 1–3). Remodeling parameters were similar in HGC
and LGC groups, except for FP(a1), which was signifi-
cantly lower in HGC than in LGC (36 6 10 days vs. 53 6
14 days, respectively; p , 0.05).
LGC, when compared with PMOP, only showed sig-
nificant lower W.Th (24.6 6 4.5 mm vs. 30.3 6 2.5 mm,
respectively; p , 0.0005), Aj.AR/BS (0.22 6 0.17 mm/
day vs. 0.83 6 0.73 mm /day, respectively; p , 0.05),
and BFR/BS (0.016 6 0.022 mm3/mm2 per day vs.
0.037 6 0.016 mm3/mm2 per day, respectively; p , 0.05),
with increased N.Oc/BS (0.13 6 0.12 mm21 vs. 0.06 6
0.10 mm21, respectively; p , 0.05). In addition, the
HGC group compared with PMOP showed decreased
Tb.N and FP(a1) (36 6 10 days vs. 53 6 11 days; p ,
0.05) and increased MaSV. After adjustment for BV/TV,
ICI was the only parameter significantly higher in HGC,
among those reflecting microarchitecture, with respect to
the two other groups (p , 0.0005).
DISCUSSION
At the histological level, previous studies have found that
PMOP patients with respect to normal women showed a
significant decrease of about 40% in cancellous bone vol-
ume, Tb.Th, Tb.N, W.Th, and in the FP(a1). In addition,
there were no significant differences in bone formation at
the tissue and BMU levels. Moreover, a significant increase
in Tb.Sp and osteoclast number was observed.(21,22) The
same results were observed in GIOP patients compared with
normal age-matched controls, even if, in that study, the
lower values of Tb.Th and W.Th were attributed principally
to depressed formation at the cell level because of decreased
lifespan of the cells.(19,20)
All the GC-treated women in our study were menopausal.
Thus, an interesting aim of the study was to evaluate pos-
sible specific effects of GC on bone loss in addition to the
menopause-related ones.(21,32) As for the remodeling, we
found increased bone resorption expressed as ES/BS and
FIG. 1. Bone microarchitecture in
PMOP and GIOP caused by LGC and
HGC (mean 6 SD; *p , 0.05; **p ,
0.001;***p , 0.0005).
TABLE 2. PARAMETERS OF TRABECULAR STRUCTURE AND MICROARCHITECTURE IN PMOP AND GIOP
Parameters PMOP (22) GIOP (22) p
W.Th (mm)a 30.3 6 2.5 22.8 6 3.1 ,0.0001
BV/TV (%) 16.4 6 5.3 12.1 6 4.8 ,0.01
Tb.N (/mm) 1.17 6 0.20 1.03 6 0.32 NS
Tb.Sp (mm) 746 6 180 965 6 439 ,0.05
Tb.Th (mm) calculateda 109 6 27 90 6 21 ,0.05
Tb.Th (mm) measureda 110 6 25 91 6 21 ,0.05
N.Nd/TV (/mm3) 0.64 6 0.38 0.51 6 0.42 NS
N.Nd-Nd/TV (/mm3) 0.47 6 0.40 0.36 6 0.47 NS
L.Nd-Nd/TSL (%) 0.26 6 0.19 0.16 6 0.17 NS
Nd.Tm 0.57 6 0.47 0.38 6 0.35 NS
E/TV (/mm3) 20.22 6 0.15 20.29 6 0.24 NS
TBPf 2.26 6 1.62 3.37 6 2.24 NS
ICI 13.64 6 19.64 46.51 6 53.20 ,0.01
MaSV (mm3) 0.59 6 0.13 0.53 6 0.13 NS
a Adjusted for obliquity.
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N.Oc/BS as in PMOP, but at a significantly higher degree.
This could be related to the effect of high doses of GCs in
further lowering estrogen levels, which could increase re-
modeling space.(33)
On the contrary, the bone formation was decreased in
GIOP with respect to PMOP at all three levels, cell, BMU,
and tissue. These changes were associated with lower W.Th,
noted even with the low cumulative dose. This finding was
likely to be caused by a lower osteoblastic apposition rate,
which resulted from both a reduced O.Th and a trend for a
shorter FP(a1), associated with similar MAR. Decreased
W.Th has previously been described in GIOP,(18–22) but in
those studies neither dose nor time influence were taken into
account. In our study, the importance of the cumulative dose
was emphasized, 10 g corresponding to a high risk of
osteoporosis, as previously shown by Joseph.(34) Similar
results in bone remodeling parameters were observed when
we compared low and high cumulative dose groups. In
addition, the FP(a1) was significantly reduced in the HGC
group, suggesting a dose-related toxic effect of GC treat-
ment on the osteoblasts. In fact, these findings suggested
that while decreased osteoblastic activity was already asso-
ciated with low cumulative doses of GC, only prolonged
exposure to this treatment could reduce the period of time in
which these cells work actively to synthesize bone matrix.
For many years, microarchitecture evaluation has been
considered as an interesting approach to histological eval-
uation of bone. Particularly in the last decade, many param-
eters have been suggested and evaluated to describe directly
or indirectly the trabecular network. However, all these
microarchitecture parameters have been evaluated in 2D
sections even if the connectivity is a 3D property of bone
FIG. 2. Node parameters of strut anal-
ysis in PMOP and GIOP caused by LGC
and HGC (mean 6 SD; *p , 0.05;
**p , 0.01).
FIG. 3. Indirect parameters of bone
microarchitecture in PMOP and GIOP
caused by LGC and HGC (mean 6 SD;
*p , 0.05; **p , 0.005; ***p ,
0.0005).
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structure. Thus, using 2D images, there are some limitations
and information about connectivity may only be inferred.
Therefore, the strut analysis in our study only focused on the
nodes, but we have also evaluated other parameters, some of
which were previously found to be correlated to 3D mea-
sures.(25) Nevertheless, changes in microarchitecture also
have been proposed to explain the disproportional decrease
in fracture incidence with respect to relative gain in bone
mass with new antiresorptive agents. Recently, it has been
found that trabecular microarchitecture was a major and
independent determinant of vertebral fractures in middle-
aged men with severe osteopenia.(35) From another point of
view, it also has been suggested that even if the deteriora-
tion of trabecular architecture is a contributory effect to
bone fragility, it is not necessary to repair the architectural
defects to prevent fractures.(36) Hence, further studies are
needed to define the effective relationship between trabec-
ular architecture, bone loss, and fracture risk.
In our evaluation, no microarchitectural differences were
observed between GIOP and PMOP. On the contrary, dif-
ferent results were found when the GIOP group was divided
according to cumulative doses of GC. In fact, HGCs were
associated with important alterations of the trabecular net-
work with respect to LGC and PMOP groups. These mi-
croarchitectural changes were characterized by major bone
loss with trabecular thinning, which also were less numer-
ous and highly disconnected. The high value of TBPf,
MaSV, ICI, node-related parameters, and a positive value of
E/TV proved these findings. Indeed, the different parame-
ters that evaluate microarchitecture appeared consistent,
according to previous published studies,(24–27) and could
well discriminate between different degrees of connectivity
of the trabecular network. This is an important finding that
confirms microarchitecture as a relevant approach in the
assessment of connectivity because of the consistency of
different evaluations, which are certainly not casual. These
results were similar to those reported in osteoporotic men
compared with controls.(20) Even if no significant difference
was noted in any parameter of bone microarchitecture be-
tween LGC and PMOP groups, there was a trend to a
highest number of nodes (higher N.Nd/TV and N.Nd-Nd/
TV) and a better connectivity (lower E/TV) in LGC versus
PMOP. These findings, according to previous studies,(22)
suggested a different pathway of GIOP with respect to
PMOP, characterized by progressive thinning of the trabec-
ulae, without early plate perforations, at least after low
exposure to GC. This could be caused by transiently lower
or depressed osteoclastic activity induced by GCs, despite
an increased number of osteoclasts and a length of the
resorption cavities (related to secondary hyperparathyroid-
ism). Even if in this context BV/TV was certainly a major
determinant to explain the different pattern of the trabecular
network among different doses of GC, nevertheless, micro-
architecture evaluation provided additional and original in-
formation about the shape and organization of trabeculae,
even in 2D sections.
From another point of view, the results of this study also
can give an interesting suggestion about the possible revers-
ibility of GC effects on bone. Previous studies have shown
a densitometric(37,38) and histological(17) recovery after
withdrawal of exogenous treatment or successful surgery (in
Cushing’s syndrome); our results suggested that over a total
intake of 10 g, which could be considered as “the point of
no return” in this context, the bone recovery could not be
possible, because of substantial and nonreversible disrup-
tion of the trabecular network. This was suggested by lower
values of structure and microarchitecture parameters and
also by higher values of indirect microarchitectural param-
eters in the HGC group, with evidence of a bone character-
ized by a low number of trabeculae, not connected and
separated by a large marrow space (ICI increased).
In summary, GC treatment with respect to PMOP is
characterized by a greater reduction in osteoblastic activity
at all three levels, cell, BMU, and tissue, which leads to
reduced bone formation. This condition was associated with
higher resorption parameters.
At the BV/TV constant, even LGC induced a reduction in
osteoblastic activity associated with trabecular thinning and
increased resorption. With HCG, these changes were asso-
ciated with a more dramatic bone loss caused by a major
loss of trabecular connectivity. Nevertheless, the number of
subjects in this study is small and there is large variability in
the measurements. Thus, larger studies should be done to
confirm these results.
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